South Korea’s clinical trial approvals rebounded in 2023, but remained lower than the peak levels in 2020-21 amid then robust R&D activity related to COVID-19. Last year's tally showed a mix of single-country and multinational trials and reflected the ongoing dominance of oncology in industry pipelines.

Contracting practices and lack of competition among large healthcare group purchasing organizations and drug wholesalers – and their impact on the generic pharmaceutical market – are among topics in request for public comments by the agency.

Contracting practices and lack of competition among large healthcare group purchasing organizations and drug wholesalers – and their impact on the generic pharmaceutical market – are among topics in request for public comments by the agency.

The Federal Trade Commission broke new ground last year in its opposition to M&A transactions and challenge of Orange Book patent listings. The biopharma community is waiting to see if deals will face similar hurdles in 2024 and whether there will be legal battles if manufacturers of drug-device combination products decline to delist their patents. Researchers advocate that the FTC extend its inquiry to device patents on GLP-1 receptor agonists, including Wegovy and Ozempic.